-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA APPROVES ZIIHERA® (ZANIDATAMAB-HRII) WITH AND WITHOUT TISLELIZUMAB PLUS CHEMOTHERAPY IN FIRST-LINE HER2+ ADVANCED GASTROESOPHAGEAL ADENOCARCINOMA

Reuters·08/25/2026 14:00:12

Please log in to view news